{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:45:24Z","timestamp":1782301524215,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Baxter Oncology GmbH"},{"DOI":"10.13039\/501100005972","name":"German Cancer Aid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"name":"H.W. & J. Hector Stifung"},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013119","name":"PharmaMar","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013119","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Blueprint Medicines"},{"name":"Incyte"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"IKF"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013733","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen-Cliag"},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ejca.2019.10.016","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T23:28:50Z","timestamp":1574897330000},"page":"152-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma"],"prefix":"10.1016","volume":"124","author":[{"given":"Joerg T.","family":"Hartmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-G.","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Gruenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Piperno-Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annegret","family":"Kunitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Hofheinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Horger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Fix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens M.","family":"Chemnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Neise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Zander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Eckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Hann von Weyhern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2019.10.016_bib1","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1200\/JCO.2006.09.7717","article-title":"Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study","volume":"25","author":"Lorigan","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.10.016_bib2","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0959-8049(01)00050-8","article-title":"Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL\/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group","volume":"37","author":"Judson","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2019.10.016_bib3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.10.016_bib4","first-page":"572","article-title":"Trofosfamide in the palliative treatment of cancer: a review of the literature","volume":"27","author":"Latz","year":"2004","journal-title":"Onkologie"},{"key":"10.1016\/j.ejca.2019.10.016_bib5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00001813-199703000-00012","article-title":"Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil","volume":"8","author":"Strumberg","year":"1997","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ejca.2019.10.016_bib6","first-page":"2485","article-title":"Trofosfamide in patients with pancreatic cancer","volume":"19","author":"Schmidt-Sandte","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2019.10.016_bib7","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/1097-0142(20001115)89:10<2131::AID-CNCR14>3.0.CO;2-J","article-title":"Oral trofosfamide and etoposide in pediatric patients with glioblastoma multiforme","volume":"89","author":"Wolff","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2019.10.016_bib8","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/0959-8049(95)00409-2","article-title":"Trofosfamide is effective in refractory non-Hodgkin's lymphoma","volume":"31","author":"Salminen","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2019.10.016_bib9","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0959-8049(97)89029-6","article-title":"Trofosfamide as a salvage treatment with low toxicity in malignant lymphoma. A phase II study","volume":"33","author":"Helsing","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2019.10.016_bib10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF00685858","article-title":"Oral trofosfamide: an active drug in the treatment of soft-tissue sarcoma","volume":"36","author":"Blomqvist","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2019.10.016_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00001813-199906000-00004","article-title":"Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma","volume":"10","author":"Kollmannsberger","year":"1999","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ejca.2019.10.016_bib12","first-page":"1899","article-title":"Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas","volume":"23","author":"Hartmann","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2019.10.016_bib13","first-page":"541","article-title":"Oral trofosfamide: an active and well-tolerated maintenance therapy for adult patients with advanced bone and soft tissue sarcomas. Results of a retrospective analysis","volume":"25","author":"Reichardt","year":"2002","journal-title":"Onkologie"},{"issue":"4","key":"10.1016\/j.ejca.2019.10.016_bib14","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/pbc.21494","article-title":"Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial","volume":"50","author":"Klingebiel","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ejca.2019.10.016_bib15","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.1997.15.1.350","article-title":"Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma","volume":"15","author":"Guillou","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.10.016_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2019.10.016_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1998","journal-title":"Contr Clin Trials"},{"key":"10.1016\/j.ejca.2019.10.016_bib18","first-page":"3","article-title":"Interim safety analysis of AIO-STS 002 palliative randomised phase II metronomic trofosfamide trial in elderly patients with soft tissue sarcomas","volume":"30","author":"Hartmann","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2019.10.016_bib19","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/01.cad.0000224453.39200.d7","article-title":"Complete remission of relapsing high-grade angiosarcoma with single-agent metronomic trofosfamide","volume":"17","author":"Kopp","year":"2006","journal-title":"Anti Cancer Drugs"},{"issue":"1","key":"10.1016\/j.ejca.2019.10.016_bib20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.1999.17.1.150","volume":"17","author":"Van Glabbeke","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.10.016_bib21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0959-8049(01)00371-9","article-title":"Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer","volume":"38","author":"Borner","year":"2002","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919307798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919307798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:26:42Z","timestamp":1760732802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919307798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":21,"alternative-id":["S0959804919307798"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.10.016","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}